Landscape of primary sellar, parasellar and skull base tumours
Research type
Research Study
Full title
Investigating the functional, pathological, genetic and epigenetic landscape of primary neuroendocrine and non-endocrine tumours of the sellar and parasellar region
IRAS ID
261250
Contact name
Federico Roncaroli
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Tumours arising from the sellar and skull base overall account for about 20% of intra-cranial tumours. The symptoms of the disease caused by these tumours are often severe with a marked reduction in quality of life for patients. Additionally, they are often surgically challenging to treat.\nOur aim is too look for markers in blood and tissue that can help us identify if a patient is going to present with this disease in the future. This could also indicate how the disease will develop and progress, so we can use targeted therapy and medication to promote recovery and reduce recurrence. \n\nAdvances in molecular genetics have improved the diagnostic accuracy and patient stratification, and have allowed for the identification of specific genetic defects for familial and sporadic tumours but our knowledge on the causes of these tumours and our ability to treat patients successfully is still limited. \n\nThis projects aims to investigate and sellar and skull tumours as a whole to further improve their diagnosis and the stratification of patients in view targeted, individualised treatments. Salford Royal Hospital is a leading neurology hospital in the UK and there are a number of diverse experts in the field involved in this study. Participants will have a low level of intrusion when taking part in the study as we aim to use surplus tissue.\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
19/NS/0167
Date of REC Opinion
11 Oct 2019
REC opinion
Favourable Opinion